

Biocon Biologics Finland OY
BALANCE SHEET AS AT MARCH 31, 2024

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>March 31, 2024</u>
ASSETS		
Non-current assets		
Deferred tax asset (net)		6
Total non-current assets		6
Current assets		
Financial assets		
(i) Trade receivables	1	208
(ii) Cash and cash equivalents	2	70
Other current assets	3	8
Total current assets		286
TOTAL		292
EQUITY AND LIABILITIES		
Equity		
Equity share capital	4	-
Other equity	5	10
Total equity		10
Current liabilities		
Financial liabilities		
(i) Trade payables	6	187
Income-tax liability (net)		9
Provisions	7	69
Other current liabilities	8	17
Total current liabilities		282
TOTAL		292

Biocon Biologics Finland OY**STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED MARCH 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>Period ended</u> <u>March 31, 2024</u>
Income		
Other operating income	9	399
Total revenue (I)		<u>399</u>
Expenses		
Purchases of traded goods	10	32
Employee benefits expense	11	230
Depreciation		-
Other expenses	12	124
Total expenses (II)		<u>386</u>
Profit before tax		<u>13</u>
Tax expense		
Current tax		9
Deferred Tax		(6)
Total tax expense		<u>3</u>
Profit for the period		<u><u>10</u></u>

Biocon Biologics Finland OY**STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED MARCH 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

	Period ended March 31, 2024
I Cash flows from operating activities	
Profit after tax	10
<u>Adjustments to reconcile profit before tax to net cash flows:</u>	
Tax expense	3
Operating profit before working capital changes	<u>13</u>
Movements in working capital	
Decrease/(Increase) in trade receivables	(208)
(Increase) in loans and advances and other assets	(8)
Increase in trade payable, other liabilities and provisions	273
Cash generated from operations	<u>70</u>
Direct taxes paid	-
Net cash flow generated from operating activities	<u><u>70</u></u>
IV Net increase/(decrease) in cash and cash equivalents (I + II + III)	70
V Effect of exchange differences on cash and cash equivalents held in foreign currency	-
VI Cash and cash equivalents at the beginning of the year	-
VIII Cash and cash equivalents at the end of the year (IV + V + VI)	<u><u>70</u></u>
Reconciliation of cash and cash equivalents as per statement of cash flow	
Cash and cash equivalents	
Balances with banks - on current accounts	70
Cash on hand	-
	<u>70</u>
Total cash and cash equivalents [Refer note 2]	<u><u>70</u></u>

Biocon Biologics Finland OY**Notes to financial statements for the period ended March 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

March 31, 2024**1. Trade receivables****Other Receivables**

Outstanding for a period less than six months from the date they are due for payment

Unsecured, considered good

209

209**2. Cash and cash equivalents**

Balances with banks:

On current accounts

70

70**3. Other current assets**

Advance to suppliers

Prepayments

Unbilled revenues

-

8

-

8**4. Share capital**

1 Equity share of EUR 0 each

-

-

5. Other equity**Surplus/(deficit) in the statement of profit and loss**

Balance as per the last financial statements

Profit / (Loss) for the period

-

10

Net surplus/(deficit) in the statement of profit and loss**10****Total other equity****10****6. Trade payables****187****7. Provisions****Current**

Compensated absences

69

69**8. Other liabilities****(a) Current liabilities**

Statutory liabilities

17

17

Biocon Biologics Finland OY**Notes to financial statements for the period ended March 31, 2024**

(All amounts in EUR Thousands, except share data and unless otherwise stated)

**Period ended
March 31, 2024**

9. Other operating income

Support service cross charge to Group Companies	399
Interest income	-
	<hr/>
	399
	<hr/>

10. Purchase of traded goods

	32
	<hr/>
	32
	<hr/>

11. Employee benefits expense

Salaries, wages and bonus	230
	<hr/>
	230
	<hr/>

12. Other expenses

Rent	4
Legal and professional fees	73
Travelling and conveyance	25
Sales promotion expenses	16
Printing and stationery	5
Communication expenses	1
	<hr/>
	124
	<hr/>